Medicare Enrolled

Dr. Marjorie Van De Stouwe, MD

Rheumatology · Rockville Centre, NY
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
30 HEMPSTEAD AVE STE 160, Rockville Centre, NY 11570
5168728235
In practice since 2006 (20 years)
NPI: 1962427138 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Van De Stouwe from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Van De Stouwe? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Van De Stouwe

Dr. Marjorie Van De Stouwe is a rheumatology specialist in Rockville Centre, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Van De Stouwe performed 42,228 Medicare services across 830 unique beneficiaries.

Between the years covered by Open Payments, Dr. Van De Stouwe received a total of $7,145 from 31 pharmaceutical and/or device companies across 427 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Van De Stouwe is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 8% volume in NY $7,145 industry payments

Medicare Practice Summary

Medicare Utilization ↗
42,228
Medicare services
Top 8% in NY for rheumatology
830
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,111 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
25,450 $11 $40
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
5,770 $26 $150
Denosumab injection (Prolia/Xgeva) 4,500 $18 $25
Infliximab-abda biosimilar injection, 10 mg
This code represents the administration of a 10 mg dose of infliximab-abda, a biosimilar medication. It covers the injection of this specific pharmaceutical product.
3,520 $31 $150
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
866 $111 $185
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
543 $1 $25
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
395 $27 $246
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
392 $124 $400
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
146 $59 $250
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
107 $12 $97
Methylprednisolone acetate injection, 80 mg
An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication.
79 $9 $100
Urinalysis, manual
A manual laboratory examination of a urine sample to check for various substances and cells.
78 $3 $10
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
64 $8 $10
Ultrasound-guided large joint aspiration or injection
This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint.
58 $95 $300
Complete ultrasound scan of joint
An ultrasound exam that uses sound waves to create detailed images of a joint. This procedure allows for the visualization of the joint's internal structures.
58 $49 $200
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
52 $148 $400
Erythrocyte sedimentation rate (ESR) test
A blood test that measures how quickly red blood cells settle in a test tube to detect inflammation in the body. This specific method is performed manually rather than using an automated machine.
45 $4 $10
Tendon or ligament injection
A procedure involving the injection of medication into a tendon or ligament.
41 $54 $250
Methylprednisolone injection, up to 125 mg
An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg.
33 $4 $35
Ultrasound guidance for needle placement
Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure.
31 $55 $200
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
76.5% high complexity
20.9% medium
2.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$7,145
Total received (2018-2024)
Avg $1,021/year across 7 years
Top 34% in NY for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
31
Companies
427
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,329 (88.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$816 (11.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,005
2023
$639
2022
$608
2021
$974
2020
$846
2019
$1,582
2018
$1,491

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$193
GlaxoSmithKline, LLC.
$187
ANI Pharmaceuticals, Inc.
$176
AstraZeneca Pharmaceuticals LP
$170
Janssen Biotech, Inc.
$89
UCB, Inc.
$70
Novartis Pharmaceuticals Corporation
$50
SCILEX PHARMACEUTICALS INC.
$31
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
Mallinckrodt Hospital Products Inc.
$19
Top 3 companies account for 55.3% of 2024 payments
All-time payments by company (2018-2024) ›
Horizon Therapeutics plc
$1,061
GlaxoSmithKline, LLC.
$930
Janssen Biotech, Inc.
$906
Amgen Inc.
$853
Genentech USA, Inc.
$532
AstraZeneca Pharmaceuticals LP
$393
Merck Sharp & Dohme Corporation
$315
UCB, Inc.
$301
Novartis Pharmaceuticals Corporation
$217
E.R. Squibb & Sons, L.L.C.
$215
Mallinckrodt Enterprises LLC
$210
Organon LLC
$180
ANI Pharmaceuticals, Inc.
$176
PFIZER INC.
$171
Genentech, Inc.
$152
Endo Pharmaceuticals Inc.
$82
Mallinckrodt Hospital Products Inc.
$77
Mallinckrodt LLC
$50
Lilly USA, LLC
$43
Flexion Therapeutics, Inc.
$43
Aurinia Pharma U.S., Inc.
$33
Horizon Pharma plc
$33
SCILEX PHARMACEUTICALS INC.
$31
Takeda Pharmaceuticals U.S.A., Inc.
$21
Radius Health, Inc.
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
Celgene Corporation
$18
DePuy Synthes Sales Inc.
$16
Bioventus LLC
$15
Ironwood Pharmaceuticals, Inc
$15
AbbVie, Inc.
$13
Top 3 companies account for 40.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · BENLYSTA · COSENTYX · Cimzia · DUZALLO · EVENITY · Erivedge · FORTEO · GELSYN 3 · HADLIMA · Humira · INFLECTRA · KRYSTEXXA · LUPKYNIS · NEXPLANON · ORENCIA · ORTHOVISC · PURIFIED CORTROPHIN GEL · Prolia · REMICADE · RENFLEXIS · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SPEVIGO · STELARA · TALTZ · TAVNEOS · TREMFYA · Tymlos · UPLIZNA · Uloric · XELJANZ · XIAFLEX · Xolair · ZTLido · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Rockville Centre?
Compare rheumatologists in the Rockville Centre area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
315
Per 100K population
22.7
County median income
$143,408
Nearest hospital
MOUNT SINAI SOUTH NASSAU
2.3 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Van De Stouwe is a mixed practice specialist, with above-average Medicare volume (top 8% in NY), with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Van De Stouwe experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Van De Stouwe performed 25,450 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Van De Stouwe receive payments from pharmaceutical companies?
Yes. Dr. Van De Stouwe received a total of $7,145 from 31 companies across 427 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Van De Stouwe's costs compare to other rheumatologists in Rockville Centre?
Dr. Van De Stouwe's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Van De Stouwe) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →